A comprehensive view of Biogen Inc.. This page highlights a small sample of our full coverage.
For real-time access, please log in to your Tissue & Hygiene Market Intelligence Service.

Recent Articles

sample of recent headlines, press releases and get more..

UCLA study finds wide coverage of Alzheimer's drug Leqembi would raise future costs for US Medicare health plan by US$2B-US$5B/year; drugmakers Eisai, Biogen estimate Leqembi would be used to treat 100,000 US patients in first three years on the market

FDA grants accelerated approval for Biogen's Qalsody injectable to treat ALS in adults who have a mutation in SOD1 gene; Qalsody is the first approved treatment to target a genetic cause of ALS.

Biogen licenses Alzheimer's drug program from Denali Therapeutics for an undisclosed sum, aiming to develop antibody drugs targeting amyloid beta in the brain

FDA advisor committee supports conditional clearance of Biogen’s tofersen ALS drug; tofersen treats ALS caused by SOD1 gene mutation, which is estimated to be responsible for less than 500 of the approximately 30,000 ALS cases in the US

FDA grants accelerated approval to Biogen and Eisai's anti-amyloid beta protofibril antibody candidate Leqembi lecanemab to treat early Alzheimer's disease; Eisai has set wholesale acquisition cost for the drug at US$26,500 per year

Ask us about our Tissue & Hygiene market view

Trending Chart

Interactive chart with headline count